WO2008065097A2 - Stabilized solid pharmaceutical composition of candesartan cilexetil - Google Patents
Stabilized solid pharmaceutical composition of candesartan cilexetil Download PDFInfo
- Publication number
- WO2008065097A2 WO2008065097A2 PCT/EP2007/062849 EP2007062849W WO2008065097A2 WO 2008065097 A2 WO2008065097 A2 WO 2008065097A2 EP 2007062849 W EP2007062849 W EP 2007062849W WO 2008065097 A2 WO2008065097 A2 WO 2008065097A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stabilizing agent
- candesartan cilexetil
- weight
- composition
- crc
- Prior art date
Links
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical group C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 229960004349 candesartan cilexetil Drugs 0.000 title claims abstract description 53
- 239000007787 solid Substances 0.000 title claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 68
- 239000003381 stabilizer Substances 0.000 claims abstract description 55
- 150000001298 alcohols Chemical class 0.000 claims abstract description 36
- 150000002148 esters Chemical class 0.000 claims abstract description 29
- 239000013543 active substance Substances 0.000 claims abstract description 20
- -1 saturated fatty acid alkaline salts Chemical class 0.000 claims abstract description 19
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims abstract description 15
- 150000004671 saturated fatty acids Chemical class 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 10
- 235000003441 saturated fatty acids Nutrition 0.000 claims abstract description 10
- 150000002170 ethers Chemical class 0.000 claims abstract description 7
- 235000020957 pantothenol Nutrition 0.000 claims abstract description 6
- 239000011619 pantothenol Substances 0.000 claims abstract description 6
- 229940101267 panthenol Drugs 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 239000003826 tablet Substances 0.000 claims description 20
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 13
- 239000001069 triethyl citrate Substances 0.000 claims description 13
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 13
- 235000013769 triethyl citrate Nutrition 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 11
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 9
- 239000012752 auxiliary agent Substances 0.000 claims description 9
- 229960002003 hydrochlorothiazide Drugs 0.000 claims description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 9
- 239000011230 binding agent Substances 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000002934 diuretic Substances 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- 238000007906 compression Methods 0.000 claims description 7
- 238000005469 granulation Methods 0.000 claims description 7
- 230000003179 granulation Effects 0.000 claims description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- 229920002261 Corn starch Polymers 0.000 claims description 6
- 239000008120 corn starch Substances 0.000 claims description 6
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical group CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 229940060384 isostearyl isostearate Drugs 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 230000000181 anti-adherent effect Effects 0.000 claims description 4
- 239000003911 antiadherent Substances 0.000 claims description 4
- 230000006835 compression Effects 0.000 claims description 4
- 230000001882 diuretic effect Effects 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 238000000465 moulding Methods 0.000 claims description 4
- 239000005541 ACE inhibitor Substances 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 3
- ULBTUVJTXULMLP-UHFFFAOYSA-N butyl octadecanoate Chemical group CCCCCCCCCCCCCCCCCC(=O)OCCCC ULBTUVJTXULMLP-UHFFFAOYSA-N 0.000 claims description 3
- 229940030606 diuretics Drugs 0.000 claims description 3
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000006186 oral dosage form Substances 0.000 claims description 3
- MQOCIYICOGDBSG-UHFFFAOYSA-M potassium;hexadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCC([O-])=O MQOCIYICOGDBSG-UHFFFAOYSA-M 0.000 claims description 3
- 229940124549 vasodilator Drugs 0.000 claims description 3
- 239000003071 vasodilator agent Substances 0.000 claims description 3
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000004040 coloring Methods 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 2
- 125000001033 ether group Chemical group 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 abstract description 6
- 238000009472 formulation Methods 0.000 abstract description 4
- 239000008184 oral solid dosage form Substances 0.000 abstract 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 150000004665 fatty acids Chemical class 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- ROBFUDYVXSDBQM-UHFFFAOYSA-N hydroxymalonic acid Chemical compound OC(=O)C(O)C(O)=O ROBFUDYVXSDBQM-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- YIWUKEYIRIRTPP-UHFFFAOYSA-N 2-ethylhexan-1-ol Chemical compound CCCCC(CC)CO YIWUKEYIRIRTPP-UHFFFAOYSA-N 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 235000004866 D-panthenol Nutrition 0.000 description 2
- 239000011703 D-panthenol Substances 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NQDZCRSUOVPTII-UHFFFAOYSA-N 10-methylundecan-1-ol Chemical compound CC(C)CCCCCCCCCO NQDZCRSUOVPTII-UHFFFAOYSA-N 0.000 description 1
- XUJLWPFSUCHPQL-UHFFFAOYSA-N 11-methyldodecan-1-ol Chemical compound CC(C)CCCCCCCCCCO XUJLWPFSUCHPQL-UHFFFAOYSA-N 0.000 description 1
- ZKBSDMGDEJPNGS-UHFFFAOYSA-N 2,3-dihydroxypropanoic acid Chemical compound OCC(O)C(O)=O.OCC(O)C(O)=O ZKBSDMGDEJPNGS-UHFFFAOYSA-N 0.000 description 1
- OAYXUHPQHDHDDZ-UHFFFAOYSA-N 2-(2-butoxyethoxy)ethanol Chemical compound CCCCOCCOCCO OAYXUHPQHDHDDZ-UHFFFAOYSA-N 0.000 description 1
- DJCYDDALXPHSHR-UHFFFAOYSA-N 2-(2-propoxyethoxy)ethanol Chemical compound CCCOCCOCCO DJCYDDALXPHSHR-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- COBPKKZHLDDMTB-UHFFFAOYSA-N 2-[2-(2-butoxyethoxy)ethoxy]ethanol Chemical compound CCCCOCCOCCOCCO COBPKKZHLDDMTB-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- NJYBZXINKWROMG-UHFFFAOYSA-N 2-chloro-5-(dimethylaminocarbamoyl)benzenesulfonamide Chemical compound CN(C)NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NJYBZXINKWROMG-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- OORRCVPWRPVJEK-UHFFFAOYSA-N 2-oxidanylethanoic acid Chemical compound OCC(O)=O.OCC(O)=O OORRCVPWRPVJEK-UHFFFAOYSA-N 0.000 description 1
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 1
- KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- LBXHRAWDUMTPSE-AOOOYVTPSA-N 4-chloro-N-[(2S,6R)-2,6-dimethyl-1-piperidinyl]-3-sulfamoylbenzamide Chemical compound C[C@H]1CCC[C@@H](C)N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 LBXHRAWDUMTPSE-AOOOYVTPSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- PWDGTQXZLNDOKS-UHFFFAOYSA-N 5-[(phenylsulfonyl)amino]-1,3,4-thiadiazole-2-sulfonamide Chemical compound S1C(S(=O)(=O)N)=NN=C1NS(=O)(=O)C1=CC=CC=C1 PWDGTQXZLNDOKS-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- LPEKGGXMPWTOCB-UHFFFAOYSA-N 8beta-(2,3-epoxy-2-methylbutyryloxy)-14-acetoxytithifolin Natural products COC(=O)C(C)O LPEKGGXMPWTOCB-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- MRABAEUHTLLEML-UHFFFAOYSA-N Butyl lactate Chemical compound CCCCOC(=O)C(C)O MRABAEUHTLLEML-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- DUFKCOQISQKSAV-UHFFFAOYSA-N Polypropylene glycol (m w 1,200-3,000) Chemical compound CC(O)COC(C)CO DUFKCOQISQKSAV-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229950009255 alipamide Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- HTQMVQVXFRQIKW-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 HTQMVQVXFRQIKW-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229960004070 clopamide Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- 150000003903 lactic acid esters Chemical class 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000002346 layers by function Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940057867 methyl lactate Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229940017144 n-butyl lactate Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- QAOJADINKLMTRR-UHFFFAOYSA-N octan-3-yl 16-methylheptadecanoate Chemical compound CCCCCC(CC)OC(=O)CCCCCCCCCCCCCCC(C)C QAOJADINKLMTRR-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- ILVGAIQLOCKNQA-UHFFFAOYSA-N propyl 2-hydroxypropanoate Chemical compound CCCOC(=O)C(C)O ILVGAIQLOCKNQA-UHFFFAOYSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940045845 sodium myristate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940045870 sodium palmitate Drugs 0.000 description 1
- 229940080350 sodium stearate Drugs 0.000 description 1
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 1
- JUQGWKYSEXPRGL-UHFFFAOYSA-M sodium;tetradecanoate Chemical compound [Na+].CCCCCCCCCCCCCC([O-])=O JUQGWKYSEXPRGL-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 229940071138 stearyl fumarate Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to solid pharmaceutical compositions comprising candesartan cilexetil, which exhibit a high stability of the active substance.
- the invention also relates to the use thereof in the preparation of solid oral dosage forms of candesartan cilexetil.
- Candesartan cilexetil is the INN (International Nonproprietary Name) of 2-ethoxy-1 -[[2'-(1 H-tetrazol-5-yl)[1 ,1 '-biphenyl]-4-yl]methyl]-1 H- benzimidazole-7-carboxylic acid, 1 -[[(cyclohexyloxy)carbonyl]oxy]ethyl ester having the following structural formula:
- Candesartan cilexetil is an active ingredient, which was disclosed for the first time in European Patent Application EP-A-0459136. Due to its capacity in acting as an angiotensin Il receptor antagonist, it is used as an antihypertensive agent.
- Patent Application EP-A-0546358 discloses that solid compositions including an angiotensin Il receptor antagonist as active ingredient, for example candesartan cilexetil, show a reduction in the content of active ingredient with the lapse of time due to a crystal deformation caused, for example, by the pressure, abrasion or heat applied during the granulation or compression process.
- compositions show higher stability if an oily substance selected from the group consisting of hydrocarbons, fatty acids, long-chain alcohol, esters of a fatty acid and a polyhydroxy alcohol, ethers of a long-chain alcohol and a polyhydroxy alcohol, and alkylene oxide polymers or copolymers, is incorporated into the formulation.
- Patent Application WO-A-2005/070398 discloses that the incorporation of cosolvents into the formulations of candesartan cilexetil also contributes to the stabilization of this active substance.
- Patent Application WO-A-2005/079751 discloses another technical solution for improving stability of candesartan cilexetil compositions which consists of the incorporation of lipids and phospholipids.
- lipids fatty acids and fatty acid esters, particularly, fatty acid glycerol esters are described.
- phospholipids phosphoglycerides and sphyngolipids are described.
- Patent Application WO-A-2005/084648 discloses pharmaceutical compositions of candesartan cilexetil, which are stabilized by hydrosoluble polymers, for example, xanthan gum, polyvinyl alcohol, and maltodextrin.
- the object of the present invention is a solid pharmaceutical composition comprising candesartan cilexetil, as an active substance, and a stabilizing agent.
- the invention encompasses a process for the preparation of this solid pharmaceutical composition.
- compositions for the preparation of solid oral dosage forms of candesartan cilexetil.
- Another aspect of the invention relates to a tablet containing candesartan cilexetil, which comprises the pharmaceutical composition of the invention.
- the object of the invention is a solid pharmaceutical composition for oral use comprising: a) a pharmaceutically effective amount of candesartan cilexetil, and b) a stabilizing agent selected from the group consisting of :
- the active substance of the composition of this invention is candesartan cilexetil, which may be prepared, for instance, in accordance with the process disclosed in Patent Application EP-A-0459136.
- any crystalline or amorphous form of the active ingredient may be used.
- a stable crystalline form as described in Experimental Example 1 of EP-A-0459136 is used.
- the stabilizing agent used according to the present invention is selected from the group consisting of esters of saturated fatty acids and monohydroxy alcohols, esters of hydroxycarboxylic acids and monohydroxy alcohols, ethers of CrC 4 monohydroxy alcohols and C 2 -C 9 polyhydroxy alcohols, saturated fatty acid alkaline salts, and panthenol.
- saturated fatty acids refers to those fatty acids that have a carbon-atom chain equal to or higher than C 6 , that do not have unsaturated double or triple bonds along the hydrocarbon chain, and have only one carboxylic group.
- fatty acids may be, for instance, caproic acid (C 6 ), caprilic acid (C 8 ), capric acid (Ci 0 ), lauric acid (Ci 2 ), myhstic acid (Ci 4 ), palmitic acid (Ci 6 ), stearic acid (Ci 8 ), arachidic acid (C20), behenic acid (C22), and lignoceric acid (C 24 ).
- caproic acid C 6
- caprilic acid C 8
- capric acid Ci 0
- lauric acid Ci 2
- myhstic acid Ci 4
- palmitic acid Ci 6
- stearic acid Ci 8
- arachidic acid C20
- behenic acid C22
- lignoceric acid C 24
- mixtures of saturated carboxylic acids derived from splitting hydrogenation of oils and natural fats for example, hydrogenated coconut fatty acids, hydrogenated palm fatty acids, hydrogenated rapeseed fatty acids, hydrogenated tallow fatty acids
- carboxylic acids that have a carbon-atom chain equal to or higher than C 6 and wherein the hydrocarbonated chain is branched, for example, 2-ethylhexanoic acid (branched C 8 ), and isostearic acid (branched Ci 8 ).
- Monohydroxy alcohols are those alcohols which have only one hydroxyl group.
- the term "monohydroxy alcohols” also refers to those alcohols wherein the hydrocarbonated chain is branched, such as isopropanol, isobutanol, sec-butanol, 2-ethylhexanol (branched C 8 ), isododecyl alcohol (branched Ci 2 ), isotridecyl alcohol (branched Ci 3 ), isostearyl alcohol (branched Cis), and alcohol 2-octyldodecyl (branched C 2 o).
- Hydroxycarboxylic acids are carboxylic or polycarboxylic acids that include one or more hydroxyl groups in their structure, such as, glycolic acid (hydroxyethanoic acid), lactic acid (2-hydroxypropanoic acid), glyceric acid (2,3-dihydroxypropanoic acid), tartronic acid (hydroxypropanedioic acid), malic acid (hydroxybutanedioic acid), and citric acid (2-hydroxy-1 ,2,3- propanetricarboxylic acid).
- C 2 -Cg polyhydroxy alcohols are those alcohols that have two or more hydroxyl groups in their molecule, for example, ethylenglycol, diethylenglycol, triethylenglycol, propylenglycol, dipropylenglycol, glycerin, diglycehn, triglycerin, sorbitol and sorbitan.
- Saturated fatty acid alkaline salts also denominated soaps, are constituted by a carboxylate anion derived from the saturated fatty acid chain an by an alkali metal cation, for example, lithium, sodium or potassium.
- an alkali metal cation for example, lithium, sodium or potassium.
- sodium palmitate, sodium stearate, potassium stearate, potassium palmitate, and sodium myristate may be mentioned.
- Panthenol is a common name for 2,4-dihydroxy-N-(3- hydroxypropyl)-3,3-dimethylbutanamide, which is also denominated provitamin B5.
- the compound has a chiral centre, and both the racemic form (DL- panthenol) and optically active D-panthenol are commercially available. Either of them is suitable to be used in the composition of the invention as a stabilizing agent of candesartan cilexetil.
- Esters of saturated fatty acids and monohydroxy alcohols include, for example, isopropyl myristate, isopropyl palmitate, isopropyl stearate, n- butyl stearate, 2-ethylexyl palmitate, 2-ethylexyl stearate, 2-octyldodecyl myristate, 2-ethylhexyl isostearate, isostearyl isostearate, isononyl isononanoate.
- Esters of this type are commercially available, for example, under the trade names PRISORINE ® and PRIOLUBE ® from Uniqema, or WAGLINOL ® and LAS E M U L ® from Industrial Quimica Lasem.
- the esters denominated stearates contain a mixture of C16 (palmitic) acid and Ci ⁇ (stearic) acid, wherein the latter is the major component, even though other stearates containing approximately 100% stearic acid are also commercially available.
- Suitable esters of hydroxycarboxylic acids and monohydroxy alcohols may include, for example, thethyl citrate, butyl citrate, methyl lactate, ethyl lactate, n-butyl lactate, and n-propyl lactate.
- Lactic acid esters are commercially available, for example, under the trade name PURASOLV ® from PURAC.
- Suitable ethers of CrC 4 monohydroxy alcohols and C2-C9 polyhydroxy alcohols may include, for example, diethylenglycol monoethyl ether, ethylenglycol monobutyl ether, diethylenglycol monobutyl ether, triethylenglycol monobutyl ether, thethylenglycol monoethyl, ethylenglycol monomethyl ether, and diethylenglycol mono-n-propyl ether.
- These ethers are commercially available, for example, under the trade names DOWANOL ® , CELLOSOLVE ® , and CARBITOL ® from Dow.
- the stabilizing agent is selected from the group consisting of esters of saturated fatty acids and branched C8-C20 monohydroxy alcohols, esters of saturated fatty acids and CrC 4 monohydroxy alcohols, esters of hydroxycarboxylic acids and CrC 4 monohydroxy alcohols, and ethers of CrC 4 monohydroxy alcohols and C2-C9 polyhydroxy alcohols.
- the stabilizing agent is an ester of a saturated fatty acid and a branched C8-C20 monohydroxy alcohol, more preferably it is an ester selected from the group consisting of 2-octyldodecyl myhstate and isostearyl isostearate.
- the stabilizing agent is an ester of a saturated fatty acid and a CrC 4 monohydroxy alcohol, more preferably n-butyl stearate.
- the stabilizing agent is ether of a CrC 4 monohydroxy alcohol and a C2-C9 polyhydroxy alcohol, more preferably diethylenglycol ethyl ether. More preferably the stabilizing agent is an ester of a hydroxycarboxylic acid and a CrC 4 monohydroxy alcohol, even more preferably an ester of citric acid and a CrC 4 monohydroxy alcohol, and even more preferably thethyl citrate.
- the invention also encompasses a process for the preparation of a solid pharmaceutical composition of candesartan cilexetil, which comprises mixing the active substance with the stabilizing agent and moulding the mixture.
- the process comprises mixing candesartan cilexetil with an ester of a hydroxycarboxylic acid and a CrC 4 monohydroxy alcohol, and moulding the mixture, more preferably with triethyl citrate.
- the mixture is moulded by granulation or high-pressure compression, so that granules or tablets can be prepared.
- the stabilizing agent is a solid product it can be directly added to the active substance, and the mixture may be moulded by compression. A solvent may also be added, and performing a granulation step and subsequent drying. If the stabilizing agent is a liquid product it can also be sprayed directly onto the active substance followed by kneading and granulation. If the stabilizing agent is a product wherein the melting point is in a range of approximately 3O 0 C to 9O 0 C it can be added in the melted state.
- a solution or dispersion of the stabilizing agent and the active substance may be each prepared and may be sprayed onto a pulverulent solid inert excipient, and then the composition may be conventionally kneaded, granulated and dried.
- the solvent should not exert any harmful effect on the active substance, such as for example water, ethanol, isopropyl alcohol, methylene chloride, or dimethylformamide.
- the incorporation of the stabilizing agent into the solid composition of the invention allows stabilization of the active substance in the kneading, granulation and compression process.
- different auxiliary agents may be used for preparing the solid compositions of the invention, which may be added during the appropriate phase so as to afford the appropriate mechanical and release properties.
- the auxiliary agent according to the present invention is used during the moulding phase.
- Solid dosage forms for oral administration are provided.
- compositions of the invention for the preparation of solid dosage forms of candesartan cilexetil for oral administration.
- the solid dosage forms of candesartan cilexetil for oral administration include tablets, capsules, granules, or pellets, which may eventually be coated with one of more functional and/or non-functional layers. Tablets are preferred dosage forms.
- the invention also encompasses a tablet of candesartan cilexetil comprising the composition of the invention in an amount sufficient to provide an effective unit dose of candesartan cilexetil, and at least one auxiliary agent.
- candesartan cilexetil is an effective active substance for the treatment of hypertension.
- candesartan cilexetil may be orally administered in the form of tablets.
- the effective unit dose of candesartan cilexetil may range from 1 mg to 50 mg per day, preferably from 2 mg to 30 mg per day.
- the tablets of the invention contain as stabilizing agent an ester of a hydroxycarboxylic acid and a CrC 4 monohydroxy alcohol, more preferably triethyl citrate
- the auxiliary agent may be selected from the group consisting of diluents, binders, lubricants, and disintegrating, antiadherent, colouring, sweetening, flavouring agents, and/or mixtures thereof.
- Diluents are inert excipients that facilitate compression of pulverulent materials and provide resistance to tablets.
- Suitable diluents include corn starch, microcrystalline cellulose, powdered cellulose, silicified cellulose, lactose monohydrate, anhydrous lactose, mannitol, sorbitol, sucrose, fructose, dextrose, and/or mixtures thereof.
- corn starch and mannitol are used.
- Binding agents are compounds that are able to provide cohesive properties to pulverulent material, in such a way that the fluidity of the composition is improved.
- the binding agent is selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methylcellulose, polyvinylpyrrolidone, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, and/or mixtures thereof.
- hydroxypropyl cellulose is used.
- Disintegrating agents are excipients that promote the rapid breakup of the tablet in an aqueous medium, as well as the rapid disintegration of the granule in order to release more quickly the active substance.
- Disintegrating agents may be selected from the group consisting of low- substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, crospovidone, sodium croscarmellose, and/or mixtures thereof. Disintegrating agents may be incorporated into the intragranular phase and/or into the extragranular phase.
- Lubricants and antiadherent agents are excipients that reduce interparticular friction and prevent adhesion of drug particles, and improve fluidity of granular or pulverulent compositions.
- Lubricants may be selected from the group consisting of talc, alkaline earth salts of stearic acid, specially magnesium and calcium stearate, stearic acid, glycerin palmitostearate, stearyl fumarate, and/or mixtures thereof.
- Colloidal silica is most preferred as an antiadherent agent.
- compositions of this invention may also contain sweetening and flavouring agents in order to provide acceptable organoleptic properties (flavour and taste) for patients.
- suitable sweetening agents include sodium saccharin, aspartame, mannitol, xylitol, sucrose, sorbitol and ammonium glycyrrhizinate.
- Suitable flavouring agents include fruit and plant flavours, for example orange, anise, mint, etc.
- Suitable colouring agents which may be incorporated into the tablets of the invention, may be selected from those approved for oral use.
- the tablets may be coated using conventional methods known to a person skilled in the art, as those described in Remington: The Science and Practice of Pharmacy, 20th Edition, Philadelphia, Lippincott, Williams & Wilkins, 2000 [ISBN 0 683 306472].
- film-forming agents which are used for coating the tablets, polyvinylpyrrolidone, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, hypromelose, solid polyethylenglycol, and polyvinyl alcohol may be included.
- Suitable auxiliary agents include pigments, plastifiers, and surfactants.
- auxiliary agents Information on the characteristics of auxiliary agents is described in reference handbooks available to those skilled in the art, for example in Handbook of Pharmaceutical Excipients, 4th Edition, London, Pharmaceutical Press, 2003 [ISBN 0 85369 472 9] wherein, in addition, the trade names of commercially available auxiliary agents are included.
- the concentration of candesartan cilexetil usually ranges from 0.5% to 35% by weight on the total weight of the composition, preferably from 1 % to 15%, and even more preferably from 2% to 10%.
- the concentration of the stabilizing agent may range from 0.1 % to 20% by weight on the total weight of the composition, more preferably from 0.5% to 10%, and even more preferably from 1 % to 5%.
- the solid pharmaceutical dosage form (for example tablets) may include another active substance selected from the group consisting of diuretics, vasodilators and ACE inhibitors.
- Suitable diuretics include, for example, acetazolamide, alipamide, benzolamide, clopamide, furosemide and hydrochlorothiazide.
- Suitable vasodilators include, for example, felodipine, nicardipine and nifedipine.
- Suitable ACE inhibitors include, for example, perindopril, lisinopril and ramipril.
- a diuretic agent is preferred, more preferably hydrochlorothiazide.
- the solid pharmaceutical dosage form of the invention is a tablet of candesartan cilexetil comprising: a) from 1 % to 15% by weight of candesartan cilexetil b) from 1 % to 10% by weight of binder c) from 1 % to 6% by weight of stabilizing agent selected from the group consisting of triethyl citrate, 2-octyldodecyl myhstate, isostearyl isostearate, diethylenglycol monoethyl ether, butyl stearate, DL- panthenol and potassium palmitate. d) from 47% to 96.9% by weight of diluent, e) from 0.1 % to 2% by weight of lubricant, and f) from 0% to 20% by weight of a diuretic active ingredient.
- stabilizing agent selected from the group consisting of triethyl citrate, 2-octyldodecyl myhstate, isosteary
- the binding agent is hydroxypropyl cellulose
- the stabilizing agent is triethyl citrate
- the diluent is selected from the group consisting of mannitol, lactose, corn starch and/or a mixture thereof and the lubricant is magnesium stearate.
- a preferred embodiment encompasses a tablet comprising hydrochlorothiazide as diuretic active ingredient, and more preferably in a percentage from 6% to 10% w/w.
- the weight percent refers to the total weight of the composition.
- solid pharmaceutical compositions of candesartan cilexetil containing a stabilizing agent selected from the abovementioned group have shown good stability in accelerated stability tests at 4O 0 C and 75% relative humidity temperature, and also at 5O 0 C temperature. Test results indicated that the content of degradation products in these compositions was significantly lower than the values obtained in compositions without stabilizing agent.
- the total content of degradation products with respect to the content of active ingredient in a composition comprising 4% of triethyl citrate goes from 0.30% before testing to 0.45% after standing for 28 days at 5O 0 C.
- this percentage in a similar composition but without stabilizing agent goes from 0.28% to 1.84% after 28 days at 5O 0 C.
- Example 1 Preparation of tablets containing 4 mg of candesartan cilexetil and triethyl citrate as stabilizing agent
- the resulting granulate was dried in a stove at a temperature of 5O 0 C until humidity was lower than 3%.
- the granules were sieved, and then 1.5 g (0.3%) of magnesium stearate were added and mixed.
- the lubricated granules were compressed into 130-mg tablets by using 7-mm diameter punches on a compressing machine (Fette 1021 i).
- Tablets weighing 130 mg were obtained, each one containing 4 mg of candesartan cilexetil.
- Example 9 Preparation of tablets containing 8 mg of candesartan cilexetil, 12.5 mg of hydrochlorothiazide, and triethyl citrate as stabilizing agent
- the mixture was granulated with an aqueous solution of 37.2 g (7.5%) of hydroxypropyl cellulose and 10 g (2%) of triethyl citrate as stabilizing agent.
- the resulting granulate was dried in a stove at a temperature of
- the granules were sieved, and then 1.5 g (0.3%) of magnesium stearate were added and mixed.
- the lubricated granules were compressed into 165-mg tablets by using 7-mm diameter punches on a compressing machine (Fette 1021 i).
- Tablets weighing 165 mg were obtained, each one containing 8 mg of candesartan cilexetil and 12.5 mg of hydrochlorothiazide.
- HPLC analysis was used to determine the content of impurities in the tablets at the beginning of the test period and after standing for 14 days and 28 days under the abovementioned conditions.
- the samples were prepared by placing 10 tablets in a 25-ml volumetric flask. About 3 ml of methanol were added, and the flask was immersed in an ultrasonic bath until completion of tablet disintegration. Then about 5 ml of acetonitrile were added, and the flask was immersed again in the ultrasonic bath for 15 minutes. The flask was brought to volume with acetonitrile and mixed. The obtained suspension was filtered, and the resulting solution was used for HPLC analysis in order to determine the content of impurities.
- the HPLC equipment consisted of a Waters Alliance system with
- the mobile phase was constituted of a mixture of solution A (v/v) (0.1 % v/v aqueous buffer of trifluoroacetic acid) and acetonitrile.
- the mobile phase had 45% of solution A and 55% of acetonitrile except during the 15-25 minute period, in which a mixture formed by 5% solution A and 95% acetonitrile was used.
- Table Il shows the results of the stability, expressed as a percentage of degradation products with respect to active substance found in the tablets at the beginning of test period and after storage at accelerated conditions:
- compositions of candesartan cilexetil of the present invention show good stability of the active ingredient.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a solid pharmaceutical composition containing candesartan cilexetil as active ingredient and a stabilizing agent selected from the group consisting of esters of saturated fatty acids and monohydroxy alcohols, esters of hydroxycarboxylic acids and monohydroxy alcohols, ethers of C1-C4 monohydroxy alcohols and C2-C9 polyhydroxy alcohols, saturated fatty acid alkaline salts, panthenol, and/or mixtures thereof. The invention also relates to a process for its preparation and its use for formulation of oral solid dosage forms of candesartan cilexetil. The active substance in the compositions comprising the stabilizing agent exhibits good stability over time.
Description
STABILIZED SOLID PHARMACEUTICAL COMPOSITION OF CANDESARTAN CILEXETIL
Field of the invention
The present invention relates to solid pharmaceutical compositions comprising candesartan cilexetil, which exhibit a high stability of the active substance. The invention also relates to the use thereof in the preparation of solid oral dosage forms of candesartan cilexetil.
Background of the invention
Candesartan cilexetil is the INN (International Nonproprietary Name) of 2-ethoxy-1 -[[2'-(1 H-tetrazol-5-yl)[1 ,1 '-biphenyl]-4-yl]methyl]-1 H- benzimidazole-7-carboxylic acid, 1 -[[(cyclohexyloxy)carbonyl]oxy]ethyl ester having the following structural formula:
Candesartan cilexetil is an active ingredient, which was disclosed for the first time in European Patent Application EP-A-0459136. Due to its capacity in acting as an angiotensin Il receptor antagonist, it is used as an antihypertensive agent.
Patent Application EP-A-0546358 discloses that solid compositions including an angiotensin Il receptor antagonist as active ingredient, for example candesartan cilexetil, show a reduction in the content
of active ingredient with the lapse of time due to a crystal deformation caused, for example, by the pressure, abrasion or heat applied during the granulation or compression process.
It is also described in EP-A-0546358 that these compositions show higher stability if an oily substance selected from the group consisting of hydrocarbons, fatty acids, long-chain alcohol, esters of a fatty acid and a polyhydroxy alcohol, ethers of a long-chain alcohol and a polyhydroxy alcohol, and alkylene oxide polymers or copolymers, is incorporated into the formulation. Patent Application WO-A-2005/070398 discloses that the incorporation of cosolvents into the formulations of candesartan cilexetil also contributes to the stabilization of this active substance. Among cosolvents, propylenglycol, polyethylenglycol, ethanol, glycerol, propylenglycol esters and polyethylenglycol esters are described. Patent Application WO-A-2005/079751 discloses another technical solution for improving stability of candesartan cilexetil compositions which consists of the incorporation of lipids and phospholipids. Among lipids, fatty acids and fatty acid esters, particularly, fatty acid glycerol esters are described. Among phospholipids, phosphoglycerides and sphyngolipids are described. Patent Application WO-A-2005/084648 discloses pharmaceutical compositions of candesartan cilexetil, which are stabilized by hydrosoluble polymers, for example, xanthan gum, polyvinyl alcohol, and maltodextrin.
Therefore, there is a need to provide alternative pharmaceutical compositions of candesartan cilexetil which exhibit a good stability of the active substance.
On the basis of numerous studies, the present inventors have discovered a group of stabilizing agents that allow the preparation of pharmaceutical compositions of candesartan cilexetil, wherein the active substance exhibits good stability over time in spite of the fact that it has been exposed to granulation and/or compression process.
Summary of the invention
The object of the present invention is a solid pharmaceutical composition comprising candesartan cilexetil, as an active substance, and a stabilizing agent. The invention encompasses a process for the preparation of this solid pharmaceutical composition.
Also provided is the use of this composition for the preparation of solid oral dosage forms of candesartan cilexetil.
Another aspect of the invention relates to a tablet containing candesartan cilexetil, which comprises the pharmaceutical composition of the invention.
Description of the invention
The object of the invention is a solid pharmaceutical composition for oral use comprising: a) a pharmaceutically effective amount of candesartan cilexetil, and b) a stabilizing agent selected from the group consisting of :
- esters of saturated fatty acids and monohydroxy alcohols,
- esters of hydroxycarboxylic acids and monohydroxy alcohols, - ethers of CrC4 monohydroxy alcohols and C2-C9 polyhydroxy alcohols,
- saturated fatty acid alkaline salts, and
- panthenol.
Active substance
The active substance of the composition of this invention is candesartan cilexetil, which may be prepared, for instance, in accordance with the process disclosed in Patent Application EP-A-0459136.
In the composition of the invention, any crystalline or amorphous form of the active ingredient may be used. Preferably, a stable crystalline form as described in Experimental Example 1 of EP-A-0459136 is used.
Stabilizing agent
The stabilizing agent used according to the present invention is selected from the group consisting of esters of saturated fatty acids and monohydroxy alcohols, esters of hydroxycarboxylic acids and monohydroxy alcohols, ethers of CrC4 monohydroxy alcohols and C2-C9 polyhydroxy alcohols, saturated fatty acid alkaline salts, and panthenol.
Mixtures of these stabilizing agents may also be used in the composition of the invention. For the purposes of the invention, the term "saturated fatty acids" refers to those fatty acids that have a carbon-atom chain equal to or higher than C6, that do not have unsaturated double or triple bonds along the hydrocarbon chain, and have only one carboxylic group. These fatty acids may be, for instance, caproic acid (C6), caprilic acid (C8), capric acid (Ci0), lauric acid (Ci2), myhstic acid (Ci4), palmitic acid (Ci6), stearic acid (Ci8), arachidic acid (C20), behenic acid (C22), and lignoceric acid (C24). Also included are mixtures of saturated carboxylic acids derived from splitting hydrogenation of oils and natural fats, for example, hydrogenated coconut fatty acids, hydrogenated palm fatty acids, hydrogenated rapeseed fatty acids, hydrogenated tallow fatty acids, and hydrogenated castor oil fatty acids. Also included are those carboxylic acids that have a carbon-atom chain equal to or higher than C6 and wherein the hydrocarbonated chain is branched, for example, 2-ethylhexanoic acid (branched C8), and isostearic acid (branched Ci8). Monohydroxy alcohols are those alcohols which have only one hydroxyl group. They include methanol, ethanol, n-propanol, n-butanol, n- penthanol, lauryl alcohol (C12), myristyl alcohol (Ci4), palmyl alcohol (Ci6), stearyl alcohol (Ci8), behenyl alcohol (C22)- In the context of the present invention, the term "monohydroxy alcohols" also refers to those alcohols wherein the hydrocarbonated chain is branched, such as isopropanol, isobutanol, sec-butanol, 2-ethylhexanol (branched C8), isododecyl alcohol
(branched Ci2), isotridecyl alcohol (branched Ci3), isostearyl alcohol (branched Cis), and alcohol 2-octyldodecyl (branched C2o).
Hydroxycarboxylic acids are carboxylic or polycarboxylic acids that include one or more hydroxyl groups in their structure, such as, glycolic acid (hydroxyethanoic acid), lactic acid (2-hydroxypropanoic acid), glyceric acid (2,3-dihydroxypropanoic acid), tartronic acid (hydroxypropanedioic acid), malic acid (hydroxybutanedioic acid), and citric acid (2-hydroxy-1 ,2,3- propanetricarboxylic acid).
In the context of the present invention, the term "C2-Cg polyhydroxy alcohols" are those alcohols that have two or more hydroxyl groups in their molecule, for example, ethylenglycol, diethylenglycol, triethylenglycol, propylenglycol, dipropylenglycol, glycerin, diglycehn, triglycerin, sorbitol and sorbitan.
Saturated fatty acid alkaline salts, also denominated soaps, are constituted by a carboxylate anion derived from the saturated fatty acid chain an by an alkali metal cation, for example, lithium, sodium or potassium. Among others, sodium palmitate, sodium stearate, potassium stearate, potassium palmitate, and sodium myristate may be mentioned.
Panthenol is a common name for 2,4-dihydroxy-N-(3- hydroxypropyl)-3,3-dimethylbutanamide, which is also denominated provitamin B5. The compound has a chiral centre, and both the racemic form (DL- panthenol) and optically active D-panthenol are commercially available. Either of them is suitable to be used in the composition of the invention as a stabilizing agent of candesartan cilexetil. Esters of saturated fatty acids and monohydroxy alcohols include, for example, isopropyl myristate, isopropyl palmitate, isopropyl stearate, n- butyl stearate, 2-ethylexyl palmitate, 2-ethylexyl stearate, 2-octyldodecyl myristate, 2-ethylhexyl isostearate, isostearyl isostearate, isononyl isononanoate. Esters of this type are commercially available, for example, under the trade names PRISORINE® and PRIOLUBE® from Uniqema, or WAGLINOL® and LAS E M U L® from Industrial Quimica Lasem.
In general, the esters denominated stearates contain a mixture of C16 (palmitic) acid and Ciβ (stearic) acid, wherein the latter is the major component, even though other stearates containing approximately 100% stearic acid are also commercially available. Suitable esters of hydroxycarboxylic acids and monohydroxy alcohols may include, for example, thethyl citrate, butyl citrate, methyl lactate, ethyl lactate, n-butyl lactate, and n-propyl lactate. Lactic acid esters are commercially available, for example, under the trade name PURASOLV® from PURAC. Suitable ethers of CrC4 monohydroxy alcohols and C2-C9 polyhydroxy alcohols may include, for example, diethylenglycol monoethyl ether, ethylenglycol monobutyl ether, diethylenglycol monobutyl ether, triethylenglycol monobutyl ether, thethylenglycol monoethyl, ethylenglycol monomethyl ether, and diethylenglycol mono-n-propyl ether. These ethers are commercially available, for example, under the trade names DOWANOL®, CELLOSOLVE®, and CARBITOL® from Dow.
Preferably the stabilizing agent is selected from the group consisting of esters of saturated fatty acids and branched C8-C20 monohydroxy alcohols, esters of saturated fatty acids and CrC4 monohydroxy alcohols, esters of hydroxycarboxylic acids and CrC4 monohydroxy alcohols, and ethers of CrC4 monohydroxy alcohols and C2-C9 polyhydroxy alcohols.
Preferably the stabilizing agent is an ester of a saturated fatty acid and a branched C8-C20 monohydroxy alcohol, more preferably it is an ester selected from the group consisting of 2-octyldodecyl myhstate and isostearyl isostearate.
Preferably the stabilizing agent is an ester of a saturated fatty acid and a CrC4 monohydroxy alcohol, more preferably n-butyl stearate.
Preferably the stabilizing agent is ether of a CrC4 monohydroxy alcohol and a C2-C9 polyhydroxy alcohol, more preferably diethylenglycol ethyl ether.
More preferably the stabilizing agent is an ester of a hydroxycarboxylic acid and a CrC4 monohydroxy alcohol, even more preferably an ester of citric acid and a CrC4 monohydroxy alcohol, and even more preferably thethyl citrate.
Preparation process
The invention also encompasses a process for the preparation of a solid pharmaceutical composition of candesartan cilexetil, which comprises mixing the active substance with the stabilizing agent and moulding the mixture.
Preferably the process comprises mixing candesartan cilexetil with an ester of a hydroxycarboxylic acid and a CrC4 monohydroxy alcohol, and moulding the mixture, more preferably with triethyl citrate.
Preferably the mixture is moulded by granulation or high-pressure compression, so that granules or tablets can be prepared.
For example, if the stabilizing agent is a solid product it can be directly added to the active substance, and the mixture may be moulded by compression. A solvent may also be added, and performing a granulation step and subsequent drying. If the stabilizing agent is a liquid product it can also be sprayed directly onto the active substance followed by kneading and granulation. If the stabilizing agent is a product wherein the melting point is in a range of approximately 3O0C to 9O0C it can be added in the melted state. A solution or dispersion of the stabilizing agent and the active substance may be each prepared and may be sprayed onto a pulverulent solid inert excipient, and then the composition may be conventionally kneaded, granulated and dried. In case a solvent is used, the solvent should not exert any harmful effect on the active substance, such as for example water, ethanol, isopropyl alcohol, methylene chloride, or dimethylformamide.
The incorporation of the stabilizing agent into the solid composition of the invention allows stabilization of the active substance in the kneading, granulation and compression process.
As it is known by those skilled in the art, different auxiliary agents may be used for preparing the solid compositions of the invention, which may be added during the appropriate phase so as to afford the appropriate mechanical and release properties. Preferably the auxiliary agent according to the present invention is used during the moulding phase.
Solid dosage forms for oral administration
The invention encompasses the use of the compositions of the invention for the preparation of solid dosage forms of candesartan cilexetil for oral administration.
Preferably the solid dosage forms of candesartan cilexetil for oral administration include tablets, capsules, granules, or pellets, which may eventually be coated with one of more functional and/or non-functional layers. Tablets are preferred dosage forms. The invention also encompasses a tablet of candesartan cilexetil comprising the composition of the invention in an amount sufficient to provide an effective unit dose of candesartan cilexetil, and at least one auxiliary agent.
As mentioned above, candesartan cilexetil is an effective active substance for the treatment of hypertension. For management of hypertension, candesartan cilexetil may be orally administered in the form of tablets.
The effective unit dose of candesartan cilexetil may range from 1 mg to 50 mg per day, preferably from 2 mg to 30 mg per day.
In a preferred embodiment, the tablets of the invention contain as stabilizing agent an ester of a hydroxycarboxylic acid and a CrC4 monohydroxy alcohol, more preferably triethyl citrate
The auxiliary agent may be selected from the group consisting of diluents, binders, lubricants, and disintegrating, antiadherent, colouring, sweetening, flavouring agents, and/or mixtures thereof.
Diluents are inert excipients that facilitate compression of pulverulent materials and provide resistance to tablets. Suitable diluents include corn starch, microcrystalline cellulose, powdered cellulose, silicified
cellulose, lactose monohydrate, anhydrous lactose, mannitol, sorbitol, sucrose, fructose, dextrose, and/or mixtures thereof. Preferably corn starch and mannitol are used.
Binding agents are compounds that are able to provide cohesive properties to pulverulent material, in such a way that the fluidity of the composition is improved. The binding agent is selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methylcellulose, polyvinylpyrrolidone, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, and/or mixtures thereof. Preferably hydroxypropyl cellulose is used.
Disintegrating agents are excipients that promote the rapid breakup of the tablet in an aqueous medium, as well as the rapid disintegration of the granule in order to release more quickly the active substance. Disintegrating agents may be selected from the group consisting of low- substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, crospovidone, sodium croscarmellose, and/or mixtures thereof. Disintegrating agents may be incorporated into the intragranular phase and/or into the extragranular phase.
Lubricants and antiadherent agents are excipients that reduce interparticular friction and prevent adhesion of drug particles, and improve fluidity of granular or pulverulent compositions. Lubricants may be selected from the group consisting of talc, alkaline earth salts of stearic acid, specially magnesium and calcium stearate, stearic acid, glycerin palmitostearate, stearyl fumarate, and/or mixtures thereof. Colloidal silica is most preferred as an antiadherent agent.
The compositions of this invention may also contain sweetening and flavouring agents in order to provide acceptable organoleptic properties (flavour and taste) for patients. Suitable sweetening agents include sodium saccharin, aspartame, mannitol, xylitol, sucrose, sorbitol and ammonium glycyrrhizinate. Suitable flavouring agents include fruit and plant flavours, for example orange, anise, mint, etc.
Suitable colouring agents, which may be incorporated into the tablets of the invention, may be selected from those approved for oral use.
The tablets may be coated using conventional methods known to a person skilled in the art, as those described in Remington: The Science and Practice of Pharmacy, 20th Edition, Philadelphia, Lippincott, Williams & Wilkins, 2000 [ISBN 0 683 306472]. Among the film-forming agents which are used for coating the tablets, polyvinylpyrrolidone, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, hypromelose, solid polyethylenglycol, and polyvinyl alcohol may be included. Suitable auxiliary agents include pigments, plastifiers, and surfactants.
Information on the characteristics of auxiliary agents is described in reference handbooks available to those skilled in the art, for example in Handbook of Pharmaceutical Excipients, 4th Edition, London, Pharmaceutical Press, 2003 [ISBN 0 85369 472 9] wherein, in addition, the trade names of commercially available auxiliary agents are included.
In the solid pharmaceutical dosage forms of the invention, such as granules and tablets, the concentration of candesartan cilexetil usually ranges from 0.5% to 35% by weight on the total weight of the composition, preferably from 1 % to 15%, and even more preferably from 2% to 10%. The concentration of the stabilizing agent may range from 0.1 % to 20% by weight on the total weight of the composition, more preferably from 0.5% to 10%, and even more preferably from 1 % to 5%. The solid pharmaceutical dosage form (for example tablets) may include another active substance selected from the group consisting of diuretics, vasodilators and ACE inhibitors. Suitable diuretics include, for example, acetazolamide, alipamide, benzolamide, clopamide, furosemide and hydrochlorothiazide. Suitable vasodilators include, for example, felodipine, nicardipine and nifedipine. Suitable ACE inhibitors include, for example,
perindopril, lisinopril and ramipril. A diuretic agent is preferred, more preferably hydrochlorothiazide.
In a preferred embodiment, the solid pharmaceutical dosage form of the invention is a tablet of candesartan cilexetil comprising: a) from 1 % to 15% by weight of candesartan cilexetil b) from 1 % to 10% by weight of binder c) from 1 % to 6% by weight of stabilizing agent selected from the group consisting of triethyl citrate, 2-octyldodecyl myhstate, isostearyl isostearate, diethylenglycol monoethyl ether, butyl stearate, DL- panthenol and potassium palmitate. d) from 47% to 96.9% by weight of diluent, e) from 0.1 % to 2% by weight of lubricant, and f) from 0% to 20% by weight of a diuretic active ingredient.
Preferably the binding agent is hydroxypropyl cellulose, the stabilizing agent is triethyl citrate, the diluent is selected from the group consisting of mannitol, lactose, corn starch and/or a mixture thereof and the lubricant is magnesium stearate.
A preferred embodiment encompasses a tablet comprising hydrochlorothiazide as diuretic active ingredient, and more preferably in a percentage from 6% to 10% w/w.
The weight percent refers to the total weight of the composition. Surprisingly, solid pharmaceutical compositions of candesartan cilexetil containing a stabilizing agent selected from the abovementioned group have shown good stability in accelerated stability tests at 4O0C and 75% relative humidity temperature, and also at 5O0C temperature. Test results indicated that the content of degradation products in these compositions was significantly lower than the values obtained in compositions without stabilizing agent.
For example the total content of degradation products with respect to the content of active ingredient in a composition comprising 4% of triethyl citrate goes from 0.30% before testing to 0.45% after standing for 28 days at
5O0C. On the other hand, this percentage in a similar composition but without stabilizing agent goes from 0.28% to 1.84% after 28 days at 5O0C.
The following examples are given to illustrate the invention in a sufficiently complete manner.
Examples
Example 1 Preparation of tablets containing 4 mg of candesartan cilexetil and triethyl citrate as stabilizing agent
All the percentages indicated in the examples are weight percent of the total weight of the composition.
In a vessel, 15.4 g (3.1 %) of candesartan cilexetil, 345.5 g (69.1 %) of lactose and 77.5 g (15.5%) of corn starch were mixed. The mixture was granulated with an aqueous solution of 40 g (8%) of hydroxypropyl cellulose and 20 g (4%) of triethyl citrate as stabilizing agent.
The resulting granulate was dried in a stove at a temperature of 5O0C until humidity was lower than 3%.
The granules were sieved, and then 1.5 g (0.3%) of magnesium stearate were added and mixed.
The lubricated granules were compressed into 130-mg tablets by using 7-mm diameter punches on a compressing machine (Fette 1021 i).
Tablets weighing 130 mg were obtained, each one containing 4 mg of candesartan cilexetil.
Examples 2 to 8 Preparation of tablets containing 4 mg of candesartan cilexetil and different stabilizing agents
Using a procedure similar to that described in Example 1 , 130 mg tablets containing 4 mg of candesartan cilexetil and the stabilizing agents shown in Table 1 were prepared.
TABLE I
Example 9 Preparation of tablets containing 8 mg of candesartan cilexetil, 12.5 mg of hydrochlorothiazide, and triethyl citrate as stabilizing agent
In a vessel, 24.2 g (4.8%) of candesartan cilexetil, 37.8 g (7.6%) of hydrochlorothiazide, 316.6 g (63.3%) of lactose and 72.4 g (14.5%) of corn starch were mixed.
The mixture was granulated with an aqueous solution of 37.2 g (7.5%) of hydroxypropyl cellulose and 10 g (2%) of triethyl citrate as stabilizing agent. The resulting granulate was dried in a stove at a temperature of
5O0C until humidity was lower than 3%.
The granules were sieved, and then 1.5 g (0.3%) of magnesium stearate were added and mixed.
The lubricated granules were compressed into 165-mg tablets by using 7-mm diameter punches on a compressing machine (Fette 1021 i).
Tablets weighing 165 mg were obtained, each one containing 8 mg of candesartan cilexetil and 12.5 mg of hydrochlorothiazide.
Comparative Example Preparation of tablets containing 4 mg of candesartan cilexetil but without stabilizing agent
Using a procedure similar to that described in Example 1 , 130-mg tablets were prepared without the addition of stabilizing agents.
Example 10 Stability test
The tablets as prepared according to Examples 1 to 8 and Comparative Example were subjected to an accelerated stability test in a stove under two different conditions:
- 4O0C and 75% relative humidity (RH), and
- 5O0C
HPLC analysis was used to determine the content of impurities in the tablets at the beginning of the test period and after standing for 14 days and 28 days under the abovementioned conditions.
The samples were prepared by placing 10 tablets in a 25-ml volumetric flask. About 3 ml of methanol were added, and the flask was immersed in an ultrasonic bath until completion of tablet disintegration. Then about 5 ml of acetonitrile were added, and the flask was immersed again in the ultrasonic bath for 15 minutes. The flask was brought to volume with acetonitrile and mixed. The obtained suspension was filtered, and the resulting solution was used for HPLC analysis in order to determine the content of impurities. The HPLC equipment consisted of a Waters Alliance system with
UV detection at 254 nm, L1 -type column (according to USP specifications), at
a temperature of 250C, with a flow rate of 1 ml/min, and an injection volume of 10 μl.
The mobile phase was constituted of a mixture of solution A (v/v) (0.1 % v/v aqueous buffer of trifluoroacetic acid) and acetonitrile.
During analysis the mobile phase had 45% of solution A and 55% of acetonitrile except during the 15-25 minute period, in which a mixture formed by 5% solution A and 95% acetonitrile was used.
Table Il shows the results of the stability, expressed as a percentage of degradation products with respect to active substance found in the tablets at the beginning of test period and after storage at accelerated conditions:
TABLE Il
Therefore, it can be concluded that the compositions of candesartan cilexetil of the present invention show good stability of the active ingredient.
Claims
1.- A solid pharmaceutical composition for oral use comprising: a) a pharmaceutically effective amount of candesartan cilexetil, and b) a stabilizing agent selected from the group consisting of:
- esters of saturated fatty acids and monohydroxy alcohols
- esters of hydroxycarboxylic acids and monohydroxy alcohols,
- ethers of CrC4 monohydroxy alcohols and C2-C9 polyhydroxy alcohols,
- saturated fatty acid alkaline salts, and
- panthenol.
2.- A composition according to claim 1 characterized in that the stabilizing agent is selected from group consisting of esters of saturated fatty acids and branched C8-C2O monohydroxy alcohols, esters of saturated fatty acids and CrC4 monohydroxy alcohols, esters of hydroxycarboxylic acids and CrC4 monohydroxy alcohols, and ethers of CrC4 monohydroxy alcohols and C2-Cg polyhydroxy alcohols.
3.- A composition according to claim 2 characterized in that the stabilizing agent is an ester of a saturated fatty acid and a branched Cs-C2O monohydroxy alcohol.
4.- A composition according to claim 3 characterized in that the stabilizing agent is selected from the group consisting of 2-octyldodecyl myhstate or isostearyl isostearate.
5.- A composition according to claim 2 characterized in that the stabilizing agent is an ester of a saturated fatty acid and a CrC4 monohydroxy alcohol.
6.- A composition according to claim 5 characterized in that the stabilizing agent is n-butyl stearate.
7.- A composition according to claim 2 characterized in that the stabilizing agent is an ether of a CrC4 monohydroxy alcohol and a C2-C9 polyhydroxy alcohol.
8.- A composition according to claim 7 characterized in that the stabilizing agent is diethylenglycol ethyl ether.
9.- A composition according to claim 2 characterized in that the stabilizing agent is an ester of a hydroxycarboxylic acid and a CrC4 monohydroxy alcohol.
10.- A composition according to claim 9 characterized in that the stabilizing agent is thethyl citrate.
11.- A process for preparing a composition according to any of claims 1 to 10 comprising mixing candesartan cilexetil with the stabilizing agent, and moulding the mixture.
12.- A process according to claim 11 , wherein the stabilizing agent is an ester of a hydroxycarboxylic acid and a CrC4 monohydroxy alcohol.
13.- A process according to claim 12, wherein the ester of a hydroxycarboxylic acid and a CrC4 monohydroxy alcohol is triethyl citrate.
14.- A process according to any of claims 11 to 13 characterized in that the mixture is moulded by granulation or high-pressure compression.
15.- The use of a composition according to any of claims 1 to 10 for the preparation of solid oral dosage forms of candesartan cilexetil.
16.- The use according to claim 15 characterized in that the solid pharmaceutical forms are in the form of tablets, capsules, granules or pellets.
17.- The use according to claim 16 characterized in that the solid pharmaceutical forms are tablets.
18.- A tablet of candesartan cilexetil comprising a composition according to any of claims 1 to 10 in an amount sufficient to provide an effective unit dose of candesartan cilexetil, and at least one auxiliary agent.
19.- A tablet according to claim 18 characterized in that the auxiliary agent is selected from the group consisting of diluents, binders, lubricants, and disintegrating, antiadherent, colouring, sweetening, flavouring agents, and/or mixtures thereof.
20.- A tablet according to any of claims 18 or 19 characterized in that it comprises an ester of a hydroxycarboxylic acid and a CrC4 monohydroxy alcohol as a stabilizing agent.
21.- A tablet according to claims 20 characterized in that triethyl citrate is used as a stabilizing agent.
22.- A tablet according to any of claims 18 to 21 characterized in that the content of the stabilizing agent is from 0.1 % to 20% by weight on the total weight of the composition.
23.- A tablet according to claim 22 characterized in that the content of the stabilizing agent is from 0.5% to 10% by weight on the total weight of the composition.
24.- A tablet according to claim 23 characterized in that the content of the stabilizing agent is from 1 % to 5% by weight on the total weight of the composition.
25.- A tablet according to any of claims 18 to 24 characterized in that the content of candesartan cilexetil is from 0.5% to 35% by weight on the total weight of the composition.
26.- A tablet according to claim 25 characterized in that the content of candesartan cilexetil is from 1 % to 15% by weight on the total weight of the composition.
27.- A tablet according to claim 26 characterized in that the content of candesartan cilexetil is from 2% to 10% by weight on the total weight of the composition.
28.- A tablet according to any of claims 18 to 27 characterized in that it comprises another active ingredient selected from the group consisting of diuretics, vasodilators, and ACE inhibitors.
29. A tablet according to claim 28 characterized in that it comprises hydrochlorothiazide.
30.- A tablet of candesartan cilexetil characterized in that it comprises: a) from 1 % to 15% by weight of candesartan cilexetil b) from 1 % to 10% by weight of binder c) from 1 % to 6% by weight of stabilizing agent selected from the group consisting of triethyl citrate, 2-octyldodecyl myhstate, isostearyl isostearate, diethylenglycol monoethyl ether, butyl stearate, DL-panthenol and potassium palmitate. d) from 47% to 96,9% by weight of diluent, e) from 0.1 % to 2% by weight of lubricant, and f) from 0% to 20% of a diuretic active substance.
31.- A tablet according to claim 30 characterized in that the binder is hydroxypropyl cellulose, the stabilizing agent is triethyl citrate, the diluent is selected from the group consisting of mannitol, lactose, corn starch and/or a mixture thereof, and the lubricant is magnesium stearate.
32.- A tablet according to any of claims 30 or 31 characterized in that the diuretic active substance is hydrochlorothiazide.
33.- A tablet according to claim 32 characterized in that it comprises from 6% to 10% by weight of hydrochlorothiazide.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/516,539 US20100041644A1 (en) | 2006-11-28 | 2007-11-27 | Stabilized solid pharmaceutical composition of candesartan cilexetil |
| ES07847376T ES2426486T3 (en) | 2006-11-28 | 2007-11-27 | Candesartan cilexetil stabilized solid pharmaceutical composition |
| EP07847376.6A EP2099431B1 (en) | 2006-11-28 | 2007-11-27 | Stabilized solid pharmaceutical composition of candesartan cilexetil |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP200603089 | 2006-11-28 | ||
| ES200603089A ES2301401B1 (en) | 2006-11-28 | 2006-11-28 | STABILIZED SOLID PHARMACEUTICAL COMPOSITION OF CANDESARTAN CILEXETILO. |
| US88660807P | 2007-01-25 | 2007-01-25 | |
| US60/886,608 | 2007-01-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2008065097A2 true WO2008065097A2 (en) | 2008-06-05 |
| WO2008065097A3 WO2008065097A3 (en) | 2008-07-17 |
Family
ID=38984217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2007/062849 WO2008065097A2 (en) | 2006-11-28 | 2007-11-27 | Stabilized solid pharmaceutical composition of candesartan cilexetil |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20100041644A1 (en) |
| EP (1) | EP2099431B1 (en) |
| WO (1) | WO2008065097A2 (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009013237A2 (en) * | 2007-07-20 | 2009-01-29 | Krka, D.D. Novo Mesto | Stable solid pharmaceutical composition comprising candesartan or pharmaceutically acceptable forms thereof |
| EP2165702A1 (en) * | 2008-09-17 | 2010-03-24 | Helm AG | Stable and readily dissolved compositions of candesartan cilexetil prepared with wet granulation |
| JP2012149056A (en) * | 2010-12-28 | 2012-08-09 | Kyorin Rimedio Co Ltd | New stabilized solid formulation |
| JP2012153631A (en) * | 2011-01-25 | 2012-08-16 | Ohara Yakuhin Kogyo Kk | Method for producing tablet |
| JP2013006797A (en) * | 2011-06-24 | 2013-01-10 | Nippon Chemiphar Co Ltd | Candesartan cilexetil preparation |
| JP2013075833A (en) * | 2011-09-29 | 2013-04-25 | Nihon Generic Co Ltd | Solid preparation containing candesartan cilexetil |
| WO2014097209A1 (en) | 2012-12-21 | 2014-06-26 | Adamed Sp. Z O.O. | A pharmaceutical composition containing candesartan cilexetil and amlodipine |
| JP2015180684A (en) * | 2015-06-15 | 2015-10-15 | 日本ケミファ株式会社 | Candesartan cilexetil preparation |
| JP2017061574A (en) * | 2017-01-10 | 2017-03-30 | 日本ケミファ株式会社 | Candesartan cilexetil formulation |
| JP2018141011A (en) * | 2018-05-24 | 2018-09-13 | 日本ケミファ株式会社 | Candesartan cilexetil preparation |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008059206A1 (en) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical dosage form containing nifedipine or nisoldipine and an angiotensin II antagonist and / or a diuretic |
| BR112014027618A2 (en) | 2012-05-07 | 2017-06-27 | Bayer Pharma AG | A process for the manufacture of a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil. |
| KR101769293B1 (en) * | 2016-09-30 | 2017-08-30 | 주식회사 종근당 | Monolayer combination formulation comprising candesartan and amlodipine |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2000318A (en) * | 1933-05-22 | 1935-05-07 | James H Cannon | Cord connecter |
| US5376688A (en) * | 1992-12-18 | 1994-12-27 | R. P. Scherer Corporation | Enhanced solubility pharmaceutical solutions |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US20060034937A1 (en) * | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| AU2003225102A1 (en) | 2002-04-23 | 2003-11-10 | Bristol-Myers Squibb Company | Modified-release vasopeptidase inhibitor formulation, combinations and method |
| UY28326A1 (en) * | 2003-05-22 | 2004-06-30 | Osmotica Argentina S A | BREAKDOWN DEVICE CONTROLLED WITH A PREFORMED PASSAGE |
| JP5069001B2 (en) * | 2003-10-10 | 2012-11-07 | ベロクシス ファーマシューティカルズ エー／エス | Solid dosage form containing fibrates |
| US20050096365A1 (en) * | 2003-11-03 | 2005-05-05 | David Fikstad | Pharmaceutical compositions with synchronized solubilizer release |
| WO2005070398A2 (en) * | 2004-01-23 | 2005-08-04 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents |
| WO2005079751A2 (en) * | 2004-01-23 | 2005-09-01 | Ranbaxy Laboratories Limited | Oral pharmaceutical compositions of candesartan cilexetil |
| US20060024361A1 (en) * | 2004-07-28 | 2006-02-02 | Isa Odidi | Disintegrant assisted controlled release technology |
| WO2006074218A2 (en) * | 2005-01-06 | 2006-07-13 | Elan Pharma International Ltd. | Nanoparticulate candesartan formulations |
| CA2604970A1 (en) * | 2005-04-13 | 2006-08-17 | Lifecycle Pharma A/S | A tablet comprising a fibrate |
| CA2605183A1 (en) * | 2005-04-18 | 2006-10-26 | Rubicon Research Pvt. Ltd. | Bioenhanced compositions |
| TWI494134B (en) | 2006-06-20 | 2015-08-01 | Siegfried Generics Int Ag | Composition granule and tablet containing candesartan cilexetil and process to fabricate the tablet |
-
2007
- 2007-11-27 EP EP07847376.6A patent/EP2099431B1/en not_active Not-in-force
- 2007-11-27 WO PCT/EP2007/062849 patent/WO2008065097A2/en active Application Filing
- 2007-11-27 US US12/516,539 patent/US20100041644A1/en not_active Abandoned
Non-Patent Citations (2)
| Title |
|---|
| None |
| See also references of EP2099431A2 |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009013237A2 (en) * | 2007-07-20 | 2009-01-29 | Krka, D.D. Novo Mesto | Stable solid pharmaceutical composition comprising candesartan or pharmaceutically acceptable forms thereof |
| WO2009013237A3 (en) * | 2007-07-20 | 2009-10-29 | Krka, D.D. Novo Mesto | Stable solid pharmaceutical composition comprising candesartan or pharmaceutically acceptable forms thereof |
| EP2165702A1 (en) * | 2008-09-17 | 2010-03-24 | Helm AG | Stable and readily dissolved compositions of candesartan cilexetil prepared with wet granulation |
| JP2012149056A (en) * | 2010-12-28 | 2012-08-09 | Kyorin Rimedio Co Ltd | New stabilized solid formulation |
| JP2012153631A (en) * | 2011-01-25 | 2012-08-16 | Ohara Yakuhin Kogyo Kk | Method for producing tablet |
| JP2013006797A (en) * | 2011-06-24 | 2013-01-10 | Nippon Chemiphar Co Ltd | Candesartan cilexetil preparation |
| JP2013075833A (en) * | 2011-09-29 | 2013-04-25 | Nihon Generic Co Ltd | Solid preparation containing candesartan cilexetil |
| WO2014097209A1 (en) | 2012-12-21 | 2014-06-26 | Adamed Sp. Z O.O. | A pharmaceutical composition containing candesartan cilexetil and amlodipine |
| JP2015180684A (en) * | 2015-06-15 | 2015-10-15 | 日本ケミファ株式会社 | Candesartan cilexetil preparation |
| JP2017061574A (en) * | 2017-01-10 | 2017-03-30 | 日本ケミファ株式会社 | Candesartan cilexetil formulation |
| JP2018141011A (en) * | 2018-05-24 | 2018-09-13 | 日本ケミファ株式会社 | Candesartan cilexetil preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| US20100041644A1 (en) | 2010-02-18 |
| EP2099431A2 (en) | 2009-09-16 |
| WO2008065097A3 (en) | 2008-07-17 |
| EP2099431B1 (en) | 2013-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2099431B1 (en) | Stabilized solid pharmaceutical composition of candesartan cilexetil | |
| EP3086781B1 (en) | Pharmaceutical composition of dpp-iv inhibitor in combination with metformin | |
| EP2120884B1 (en) | Pharmaceutical composition | |
| US8501723B2 (en) | Pharmaceutical compositions comprising fesoterodine | |
| KR100922519B1 (en) | Pharmaceutical formulation having improved dissolution rate and stability for oral administration containing pelubiprofen | |
| EP3027174B1 (en) | Pharmaceutical compositions of fingolimod | |
| CA2652712A1 (en) | Stabilized pharmaceutical compositions comprising fesoterodine | |
| HUE031177T2 (en) | Solid pharmaceutical composition comprising rivaroxaban | |
| JP6895779B2 (en) | Azilsartan-containing solid pharmaceutical composition | |
| JP2011516527A (en) | Granulation of active pharmaceutical ingredients | |
| JP5798641B2 (en) | Pharmaceutical composition for oral administration | |
| EP2286800A1 (en) | Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs | |
| US8193226B2 (en) | Candesartan cilexetil | |
| WO2003082262A2 (en) | Compositions of venlafaxine base | |
| EP2033643A1 (en) | Compressed preparation | |
| JP2013014547A (en) | Composition obtained by stabilizing candesartan cilexetil and method for producing the same | |
| WO2016042493A1 (en) | Pharmaceutical compositions of fingolimod | |
| ES2426486T3 (en) | Candesartan cilexetil stabilized solid pharmaceutical composition | |
| US20110165235A1 (en) | Directly pressed aliskiren tablets | |
| JP3503222B2 (en) | Process for producing stabilized tablets of nicorandil | |
| US20110263701A1 (en) | Gabapentin enacarbil compositions | |
| US20160022661A1 (en) | Dosage Form Comprising Crizotinib | |
| TR2022002175A1 (en) | A TABLET COMPOSITION CONTAINING TOLVAPTAN AND AT LEAST ONE SURFACTANT | |
| EP4321154A1 (en) | A tablet of tolvaptan and at least one binder processed with spray granulation | |
| EP1825848A2 (en) | Stable pharmaceutical compositions comprising an HMG-CoA reductase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07847376 Country of ref document: EP Kind code of ref document: A2 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12516539 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2007847376 Country of ref document: EP |